Xenetic Biosciences, Inc. (XBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
XBIO Stock Summary
- XBIO has a market capitalization of $8,644,960 -- more than approximately merely 2.57% of US stocks.
- For XBIO, its debt to operating expenses ratio is greater than that reported by only 0.48% of US equities we're observing.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.07 for XENETIC BIOSCIENCES INC; that's greater than it is for merely 7.66% of US stocks.
- If you're looking for stocks that are quantitatively similar to XENETIC BIOSCIENCES INC, a group of peers worth examining would be ONTX, KOPN, NVCN, BYSI, and PTN.
- Visit XBIO's SEC page to see the company's official filings. To visit the company's web site, go to www.xeneticbio.com.
XBIO Valuation Summary
- In comparison to the median Healthcare stock, XBIO's price/sales ratio is 114.63% higher, now standing at 4.4.
- XBIO's EV/EBIT ratio has moved up 5 over the prior 80 months.
Below are key valuation metrics over time for XBIO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XBIO | 2023-01-20 | 4.4 | 0.5 | -1.0 | 1.0 |
| XBIO | 2023-01-19 | 4.3 | 0.5 | -1.0 | 1.0 |
| XBIO | 2023-01-18 | 4.4 | 0.5 | -1.0 | 1.0 |
| XBIO | 2023-01-17 | 4.2 | 0.4 | -0.9 | 1.1 |
| XBIO | 2023-01-13 | 3.7 | 0.4 | -0.8 | 1.2 |
| XBIO | 2023-01-12 | 3.6 | 0.4 | -0.8 | 1.2 |
XBIO Growth Metrics
- The 2 year revenue growth rate now stands at 1740.37%.
- Its 2 year net income to common stockholders growth rate is now at 58%.
- Its year over year revenue growth rate is now at 137.74%.
The table below shows XBIO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1.552557 | -5.354557 | -6.911498 |
| 2022-06-30 | 1.487576 | -5.308659 | -7.458357 |
| 2022-03-31 | 1.358469 | -5.30657 | -5.892845 |
| 2021-12-31 | 1.160692 | -4.738067 | -5.645179 |
| 2021-09-30 | 0.97942 | -4.233028 | -5.003524 |
| 2021-06-30 | 0.746085 | -4.211731 | -11.21302 |
XBIO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XBIO has a Quality Grade of C, ranking ahead of 27.04% of graded US stocks.
- XBIO's asset turnover comes in at 0.067 -- ranking 297th of 682 Pharmaceutical Products stocks.
- ARDX, BPTH, and ASLN are the stocks whose asset turnover ratios are most correlated with XBIO.
The table below shows XBIO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.067 | 1 | -17.669 |
| 2021-03-31 | 0.043 | 1 | -16.021 |
| 2020-12-31 | 0.028 | 1 | -18.158 |
| 2020-09-30 | 0.017 | 1 | -19.355 |
| 2020-06-30 | 0.009 | 1 | -25.896 |
| 2020-03-31 | 0.004 | 1 | -75.015 |
XBIO Price Target
For more insight on analysts targets of XBIO, see our XBIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
XBIO Stock Price Chart Interactive Chart >
XBIO Price/Volume Stats
| Current price | $0.58 | 52-week high | $1.25 |
| Prev. close | $0.57 | 52-week low | $0.24 |
| Day low | $0.57 | Volume | 57,700 |
| Day high | $0.58 | Avg. volume | 75,350 |
| 50-day MA | $0.40 | Dividend yield | N/A |
| 200-day MA | $0.64 | Market Cap | 8.74M |
Xenetic Biosciences, Inc. (XBIO) Company Bio
Xenetic Biosciences, Inc. operates as a biopharmaceutical company. The Company focuses on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens, as well as offers cell-based therapeutics targeting the B-cell receptor on the surface of malignant tumor cells. Xenetic Biosciences serves patients in the United States.
Latest XBIO News From Around the Web
Below are the latest news stories about XENETIC BIOSCIENCES INC that investors may wish to consider to help them evaluate XBIO as an investment opportunity.
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with ChemotherapyXenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. |
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19thJTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023. |
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch EventXenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 10:00 AM ET. |
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At AllThe performance at Xenetic Biosciences, Inc. ( NASDAQ:XBIO ) has been rather lacklustre of late and shareholders may be... |
This Is Why Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Looks AppropriateThe performance at Xenetic Biosciences, Inc. ( NASDAQ:XBIO ) has been rather lacklustre of late and shareholders may be... |
XBIO Price Returns
| 1-mo | 103.44% |
| 3-mo | 23.69% |
| 6-mo | -34.92% |
| 1-year | -39.65% |
| 3-year | -61.59% |
| 5-year | -97.82% |
| YTD | 103.44% |
| 2022 | -77.90% |
| 2021 | -36.76% |
| 2020 | 41.67% |
| 2019 | -92.68% |
| 2018 | -14.58% |
Loading social stream, please wait...